P. Walker

发表

Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome

R. D'Andrea, A. Wei, A. Dear, 2014, Blood Cancer Journal.

Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study

Shaji K. Kumar, F. Hernandez-Ilizaliturri, J. Pagel, 2021, Blood advances.

Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit.

J. Szer, C. Kirkpatrick, J. Seymour, 2016, The Journal of antimicrobial chemotherapy.

Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry.

C. Reid, E. Wood, S. Harrison, 2019, Clinical lymphoma, myeloma & leukemia.

Upfront tandem autologous non‐myeloablative allogeneic stem cell transplant in high‐risk multiple myeloma: a long‐term single‐centre experience

Phillip C Nguyen, J. Muirhead, P. Walker, 2022, Internal medicine journal.

Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma

D. Curtis, S. Avery, A. Spencer, 2017, Bone Marrow Transplantation.

Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

Tracy Holloway King, Z. McQuilten, H. Blacklock, 2022, British journal of haematology.

High‐dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC‐3) results in high first‐cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia

S. Opat, A. Schwarer, S. Avery, 2013, Internal medicine journal.

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study

A. Wei, O. Gervásio, S. Avery, 2011 .

Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse

A. Wei, E. Paul, A. Schwarer, 2013, Leukemia & lymphoma.

Bortezomib-based antibody depletion for refractory autoimmune hematological diseases.

S. Opat, S. Fleming, J. Mcfadyen, 2016, Blood advances.

Cancer Therapy : Clinical Reducing TNF Receptor 2 þ Regulatory T Cells via the Combined Action of Azacitidine and the HDAC Inhibitor , Panobinostat for Clinical Bene fi t in Acute Myeloid Leukemia Patients

A. Wei, M. Plebanski, A. Spencer, 2014 .

Reducing TNF Receptor 2+ Regulatory T Cells via the Combined Action of Azacitidine and the HDAC Inhibitor, Panobinostat for Clinical Benefit in Acute Myeloid Leukemia Patients

A. Wei, M. Plebanski, A. Spencer, 2013, Clinical Cancer Research.

DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma

G. Grigoriadis, A. Spencer, P. Fedele, 2018, Leukemia & lymphoma.

A preliminary study of the anti-κ myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with κ-restricted multiple myeloma

Edmond J. Breen, A. Spencer, K. Reed, 2019, Blood Cancer Journal.

Safe and effective use of outpatient non-myeloablative allogeneic stem cell transplantation for myeloma

A. Wei, D. Curtis, A. Schwarer, 2014, Blood Cancer Journal.

Comparison of the probability of target attainment of anidulafungin against Candida spp. in patients with acute leukaemia.

K. Patel, C. Kirkpatrick, T. Doan, 2014, International journal of antimicrobial agents.

Failure of haematopoietic recovery overcome by SCT despite invasive mucormycosis infection

G. Grigoriadis, S. Avery, A. Spencer, 2012, Bone Marrow Transplantation.

Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD)

W. Pierceall, U. Oppermann, A. Roberts, 2021, Leukemia & lymphoma.

The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR).

E. Wood, S. Harrison, Z. McQuilten, 2021, Clinical lymphoma, myeloma & leukemia.

Evaluation of EuroFlow minimal residual disease measurement and donor chimerism monitoring following tandem auto-allogeneic transplantation for multiple myeloma

A. Spencer, J. Muirhead, P. Walker, 2020, Bone Marrow Transplantation.

Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR)

E. Wood, S. Harrison, Z. McQuilten, 2021, Bone Marrow Transplantation.

Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre

S. Opat, C. Tam, M. Gilbertson, 2022, Internal medicine journal.

A phase I study of the anti-kappa monoclonal antibody, MDX-1097, in previously treated multiple myeloma patients.

G. Nichol, L. Cohen, A. Spencer, 2010 .

Impact of a lifestyle modification program on the metabolic syndrome and associated risk factors in long-term survivors of stem cell transplantation

S. Avery, D. Klarica, P. Walker, 2016, Bone Marrow Transplantation.

Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry

C. Reid, J. McNeil, E. Wood, 2016, BMC Medical Research Methodology.

Consensus guidelines for the use of empiric and diagnostic‐driven antifungal treatment strategies in haematological malignancy, 2014

S. Kirsa, N. Gilroy, T. Gottlieb, 2014, Internal medicine journal.

Noninvasive Assessment of Acute Graft-Versus-Host Disease of the Gastrointestinal Tract After Allogeneic Hemopoietic Stem Cell Transplantation Using 18F-FDG PET

V. Kalff, M. Cherk, S. Avery, 2022, The Journal of Nuclear Medicine.

Non invasive evaluation of acute graft versus host disease of the gastrointestinal tract following allogeneic haemopoietic stem cell transplantation using FDG PET

S. Roberts, V. Kalff, M. Cherk, 2012 .

Reducing TNF Receptor 2+ Regulatory T Cells via the Combined Action of Azacitidine and the HDAC Inhibitor, Panobinostat for Clinical Benefit in Acute Myeloid Leukemia Patients

A. Wei, M. Plebanski, A. Spencer, 2013, Clinical Cancer Research.

A sequential cohort study evaluating single‐agent KappaMab and KappaMab combined with lenalidomide and low‐dose dexamethasone in relapsed and/or refractory kappa light chain‐restricted multiple myeloma (AMaRC 01‐16)

J. Shortt, A. Spencer, H. Quach, 2023, British journal of haematology.

Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation

A. Wei, D. Curtis, S. Fleming, 2015, Transfusion.